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S U M M A R Y
Objectives: To assess the efﬁcacy and safety of tigecycline in comparison with other antimicrobial
treatments for infectious diseases.
Design: Databases of PubMed, Embase and the Cochrane Library were searched through Feb. 2015. The
reference lists of the initially identiﬁed articles and systemic review articles were manually searched.
Randomized controlled trials assessing tigecycline and other antibiotics for infectious diseases in adult
patients were included.
Results: Fifteen RCTs including 7689 cases were identiﬁed. We found that tigecycline was not as effective
as the comparator agents for clinical treatment success (for the clinically evaluable population, odds
ratio [OR] = 0.83, 95% conﬁdence interval [CI] = (0.73, 0.96), P=0.01; for the clinically modiﬁed intent-to-
treat (mITT) population, OR = 0.81, 95% CI = (0.72, 0.92), P=0.001). There was no signiﬁcant difference in
microbiological treatment success with lower eradication rate in tigecycline versus comparators (for the
microbiologically evaluable population, OR = 0.94, 95% CI = (0.77, 1.16), P=0.56; for the microbiological
mITT populations, OR = 0.91, 95% CI = (0.74, 1.11), P=0.35). Adverse events and all-cause mortality were
more common in the tigecycline group.
Conclusions: Tigecycline is not as effective as other antibiotics with relatively more frequency of adverse
events and higher mortality rate.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tigecycline is a broad-spectrum intravenous glycylcycline,
meeting the urgent need of overcoming the worsening antimicro-
bial resistance by surmounting the ribosomal protection and active
drug efﬂux resistance mechanism.1,2 In vitro studies have
demonstrated that tigecycline is highly active against many
bacteria, including many Gram-positive, Gram-negative, atypical,
and anaerobic organisms,3 as well as multidrug-resistant (MDR)
pathogens.4,5* Corresponding author. Department of Critical Care Medicine and Emergency,
Guangdong General Hospital, Guangdong Academy of Medical Sciences,
Guangzhou, Guangdong, People’s Republic of China, 510080.
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E-mail addresses: shenfengcai1111@126.com (F. Shen), hanqp@163.com
(Q. Han), xdaspiwn@163.com (D. Xie), wellfm@163.com (M. Fang),
zenghongke@vip.163.com (H. Zeng), yiyudeng666@163.com (Y. Deng).
http://dx.doi.org/10.1016/j.ijid.2015.08.009
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Since approved by the US FDA in June 2005, tigecycline has been
globally used for treatment of many serious infectious diseases. It
was ﬁrst approved for use for complicated skin and skin-structure
infections(c-SSSIs), complicated intra-abdominal infections(c-
IAIs), methicillin-resistant staphylococcus aureus (MRSA) infections
and vancomycin-resistant enterococci (VRE) infections. Currently, it
was used in community-acquired pneumonia (CAP), hospital-
acquired pneumonia (HAP) and diabetic foot infections (DFIs).
Four meta-analyses assessing the efﬁcacy and safety of
tigecycline versus standard antimicrobial treatment for severe
infectious diseases have been published. Cai et al6 concluded that
tigcycline monotherapy was as effective as comparison therapy.
Tasina et al7 suggested that tigecycline is no better than standard
treatment with higher frequency of adverse events. Yahav et al8
drew a conclusion that tigecycline has increased mortality.
Another meta-analysis9 demonstrated that tigecycline has a
signiﬁcant increase in mortality and noncure rates. There was
no consensus among these studies, and indeed were conﬂictingciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Flow diagram of studies identiﬁed, included, and excluded.
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tigecycline, more randomized controlled trials (RCTs) on it have
been published. Therefore it is necessary to re-evaluate the efﬁcacy
and safety of tigecycline in comparison with other antimicrobial
regimens for infectious diseases. Here we carried out an updated
meta-analysis to reexamine the efﬁcacy and safety of tigecycline
using all available data from RCTs published before 2015 Feb.
2. Design
2.1. Data sources
A protocol of objectives, search strategies, inclusion and
exclusion criteria, primary and secondary outcomes, and methods
of statistical analysis was deﬁned beforehand, following the
PRISMA statement (Preferred Reporting Items for Systematic
reviews and Meta-Analyses).10
Databases of PubMed, Embase, and the Cochrane Library were
searched through 2015 Feb. with no restriction to regions or
languages. The search terms were ‘‘tigecycline’’ or ‘‘glycylcycline’’Table 1
Characteristics of included studies
Study Design mITT population Indications C
Fomin 200512 MC, DB 817 cIAI Im
Oliva 200513 MC, DB 825 cIAI Im
Chen 201014 MC, OL 199 cIAI Im
Towﬁgh 201015 MC, OL 467 cIAI C
Qvist 201216 MC, OL 467 cIAI C
Breedt 200517 MC, DB 543 cSSSI V
Sacchidanand18 2005 MC, DB 573 cSSSI V
Matthews 201219 MC, OL 531 cSSSI A
a
O’Riordan 201520 MC, DB 150 cSSSI D
Tanaseanu 200921 MC, DB 428 CAP L
Bergallo 200922 MC, DB 418 CAP L
Freire 201023 MC, DB 934 HAP Im
Ramirez 201324 MC, DB 105 HAP Im
Florescu 200825 MC, DB 171 MRSA V
VRE li
Lauf 201426 MC, DB 1061 DFI E
MC = multicenter; DB = double-blind; OL = open-lable; cIAI = complicated intra-abdomina
acquired pneumonia; HAP = hospital-acquired pneumonia; MRSA = methicillin-resistant
infection; LR = low risk of bias; MR = moderate risk of bias; HR = high risk of bias.and ‘‘randomized’’. The reference lists of the initially identiﬁed
articles and systemic review articles were manually searched.
2.2. Study selection
Eligible studies were all available published RCTs that
compared tigecycline with any antimicrobial regimens for infec-
tious diseases in patients of more than 18 years old. The most
complete study was included when multiple studies were
describing the same population. Trials that were lack of random-
ized-control design and that were of pharmacodynamic or
pharmacokinetic interests were excluded.
2.3. Data extraction
Two reviewers (Shen & Deng) independently searched the
databases and extracted relevant data from each eligible study
using a standardized table. Any disagreement was worked out
through discussions or in consultation of senior instructors. The
following data were extracted: name of author, year of publication,
study design, numbers of population (modiﬁed intent-to-treat
(mITT) population, clinically evaluable (CE) population, clinical
modiﬁed intent-to-treat (c-mITT) population, microbiologically
evaluable (ME) population, and microbiological mITT (m-mITT)
population), type of infection, controlled regimen, treatment
duration, and time from treatment to test of cure.
2.4. Outcomes of interest
The primary outcomes were clinical treatment success and
microbiological treatment success. Secondary outcomes were
adverse events, all-cause mortality. For clinical treatment
success, data were extracted by CE population and c-mITT
population. For microbiological treatment success, data were
extracted by ME population and m-mITT population. Adverse
events rates and mortality rates from mITT population were used
in this analysis.
2.5. Quality assessment and statistical analysis
Risk of bias of studies was assessed by using the Cochrane
collaboration’s tool for assessing risk of bias11 as recommended by
the Cochrane handbook. The meta-analyses were performed byomparator drug Treatment
duration
Test of Cure Risk of bias
ipenem/cilastatin 5-14 14-35 MR
ipenem/cilastatin 5-14 14-35 MR
ipenem/cilastatin 2-14 12-37 HR
eftriaxone/metronidazole 4-14 10-21 HR
eftriaxone/metronidazole 4-14 8–44 HR
ancomycin/aztreonam 14 12-92 MR
ancomycin/aztreonam 14 12-92 MR
mpicillin-sulbactam or
moxicillin-clavulanate
7-14 8-50 HR
elaﬂoxacin or tigecycline 5–14 14–21 HR
evoﬂoxacin 7-14 10-21 LR
evoﬂoxacin 3-14 7-23 MR
ipenem/cilastatin 7-14 10-21 MR
ipenem/cilastatin 14 10-21 MR
ancomycin 7–28 12-37 MR
nezolid
rtapenem 28- 42 12-92 LR
l infection; cSSSI = complicated skin and skin-structure infection; CAP = community-
 staphylococcus aureus; VRE = vancomycin-resistant enterococci; DFI = diabetic foot
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The odds ratio (OR) and 95% conﬁdence interval (CI) were used for
all outcomes using the Mantel-Haenszel ﬁxed-effect method. We
use Chi-square test to evaluate statistical heterogeneity between
studies and deﬁned statistical signiﬁcance at P<0.05. We use the I2
statistic to quantify heterogeneity with statistical signiﬁcance set
at I2>50% according to the Cochrane handbook. When statistically
signiﬁcant heterogeneity was found, a Mantel-Haenszel random
effect model was used. We performed subgroup analyses by
infection type. Meta-regression was performed to explore the
potential confounder with use of Stata (version 12.0). Funnel plots
and Egger’s regression were used to assess potential publication
bias.
2.6. Data synthesis
We included ﬁfteen RCTs12–26 studies including 7689 cases
(3909 cases for tigecycline and 3780 cases for comparator drugs)Figure 2. Forest plot and meta-analysis of clinical cure rate for cliniaccording to the predeﬁned inclusion criteria (Figure 1). The two
reviewers agreed on 93% of studies for study selection and 87% of
studies for quality assessment.
3. Results
3.1. Characteristics of eligible studies
The main characteristics of the analysed RCTs are shown in
Table 1. The dose of tigecycline was initial 100 mg given by
intravenous [IV] infusion, followed by 50 mg IV every 12 hours in
14 studies. The remaining one study24 used two high doses of
tigecycline: initial 150 mg IV, followed by 75 mg IV every 12 hours
and initial 200 mg IV, followed by 100 mg IV every 12 hours
respectively. Only the data from the lower dose group was
extracted. Two doses of delaﬂoxacin were used in O’Riordan’s
study.20 Data from both doses (300 mg and 450 mg) was used to
compare with tigecycline respectively.cally evaluable [CE] population. M-H=Mantel-Haenszel method.
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We assessed the quality of every selected RCT using the
Cochrane collaboration’s tool for assessing risk of bias. Eight
studies had low risk for sequence generation, while the other seven
studies did not describe randomization method. Five studies had
low risk of bias for allocation concealment, while the rest of studies
did not mention the method of allocation concealment. Eleven
trials were double-blind and four were open-label. Only eight trials
had available protocols with consistent primary outcomes and
secondary outcomes reported in the protocols and publications.
3.3. Primary outcomes
3.3.1. Clinical treatment success
Pooling the data from fourteen studies12–24,26 that assessed
clinical treatment success in clinical evaluable (CE) population of
5663 patients showed signiﬁcantly lower cure rate in tigecycline
than in comparator drugs (OR = 0.83, 95% CI = 0.73 to 0.96, P=0.01)
(shown in Figure 2). The results were consistent with those of the
clinical modiﬁed intent-to-treat (c-mITT) population reported in
ten studies12–14,17,18,21–24,26 including 5617 patients. We foundFigure 3. Forest plot and meta-analysis of clinical cure rate for clinical modithat the efﬁcacy of tigecycline was signiﬁcantly lower than that of
comparator regimens (OR = 0.81, 95% CI = 0.72 to 0.92, P=0.001)
(shown in Figure 3). The heterogeneities between studies were
both small with no signiﬁcant differences in the two study
populations.
3.3.2. Microbiological treatment success
Eight studies12–14,17,18,21,22,25 reported microbiological treat-
ment success in microbiological mITT (m-mITT) populations of
2704 patients, and showed no signiﬁcant differences between
groups (OR = 0.91, 95% CI = 0.74 to 1.11, P=0.35) (shown in
Figure 4). For microbiologically assessable (ME) populations
reported in twelve studies12–19,21,22,24,25 including 2876 patients,
the microbiological treatment success for tigecycline was numeri-
cally lower than that for the comparator group with no signiﬁcant
difference (OR = 0.94, 95% CI = 0.77 to 1.16, P=0.56) (shown in
Figure 5). More speciﬁcally, treatment with tigecycline was
associated with numerically lower eradication rates for Bacteroides
fragilis, Escherichia coli, Klebsiella pneumonia and MRSA with no
signiﬁcance difference. Treatment with tigecycline was associated
with numerically higher eradication rates for Enterococcus faecalis
with no signiﬁcant difference. For MSSA, the eradication rate isﬁed intent-to-treat [c-mITT] population. M-H=Mantel-Haenszel method.
Figure 4. Forest plot and meta-analysis of microbiological cure rate for microbiological modiﬁed intent-to-treat [m-mITT] population. M-H=Mantel-Haenszel method.
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the eradication rate is signiﬁcantly higher in the tigecycline group
(shown in Table 2).
3.4. Secondary outcomes
3.4.1. Adverse events
Twelve studies12,14,15,17–23,25,26 including 6292 patients
reported different adverse events (AEs). The AEs rate is signiﬁ-
cantly higher in the tigecycline group than in the comparator drug
group (OR =1.49, 95% CI = 1.23 to 1.80, P <0.0001) (shown in
Figure 6). In terms of severe adverse events (SAEs) reported in
thirteen studies including 6663 patients, the incidence rate is also
signiﬁcantly higher in the tigecycline group than in the control
group (OR = 1.18, 95% CI = 1.03 to 1.35, P = 0.02) (shown in
Figure 7). Adverse events (AEs) of digestive system, cardiovascular
system, hemic and lymphatic system, respiratory system, meta-
bolic and nutritional and body as a whole were also evaluated
respectively. There was statistical signiﬁcance of higher AEs in the
tigecycline group when evaluating the digestive system (OR = 2.08,
95% CI = 1.53 to 2.83, P<0.00001) and body as a whole (OR = 1.21,
95% CI = 1.01 to 1.45, P = 0.04). There was no statistical signiﬁcance
of higher AEs in the hemic and lymphatic system (OR = 1.24, 95%
CI = 0.99 to 1.55, P = 0.06). There was no statistical signiﬁcance of
lower AEs in the metabolism and nutrition (OR = 0.96, 95%
CI = 0.79 to 1.16, P = 0.66) and respiratory system (OR = 0.70, 95%
CI = 0.43 to 1.14, P = 0.15). The cardiovascular AEs were signiﬁcantly
lower in the tigecycline group than in the control group (OR = 0.68,
95% CI = 0.52 to 0.88, P = 0.004) (shown in Table 2).3.4.2. All-cause mortality
Pooling the data from 14 studies12–19,21–26 that assessed all-
cause mortality in 7504 patients showed signiﬁcantly higher
mortality rate in the tigecycline group than in the control group
(4.05% and 3.07%, OR = 1.33, 95% CI = 1.03 to 1.72, P = 0.03) (shown
in Figure 8).
3.4.3. Publication bias
The funnel plot of clinical cure rate in CE population was shown
in Figure 9. All study outcomes lie inside the 95% CIs and were
evenly distributed around the vertical, indicating no evidence of
obvious publication bias; they also were not detected by Egger’s
regression test (two-tailed P = 0.817).
4. Discussion
This meta-analysis of 15 RCTs including 7689 patients com-
paring the efﬁcacy and safety of tigecycline and other antibiotic
regimens showed that tigecycline was not as effective as the
comparator drugs with more frequency of adverse effects and all-
cause mortality.
With regard to the clinical treatment success, we obtained a
result different from previous Meta-analyses6,7 which concluded
that there were no signiﬁcant differences of efﬁcacy between
tigecycline and control groups. We found a signiﬁcant decrease in
clinical treatment success of tigecycline compared with other
antibiotics with signiﬁcant difference. Clinical success rates were
signiﬁcantly lower in patients with HAPs and DFIs. This
discrepancy is probably due to inclusion of up-to-date published
Figure 5. Forest plot and meta-analysis of microbiological cure rate for microbiological evaluable [ME] population. M-H=Mantel-Haenszel method.
F. Shen et al. / International Journal of Infectious Diseases 39 (2015) 25–3330data16,19,20,24,26 in our meta-analysis, resulting from an updated
search of databases. The inferiority of tigecycline may be explained
to some extent by the following aspects. Firstly, tigecycline is a
bacteriostatic agent with mainly bacteriostatic activity.27 Second-
ly, a low concentration of tigecycline has been reported in the
epithelial lining ﬂuid28 and human bone,29 which may explain the
lower efﬁcacy in DFIs. In study of DFIs26 included in our meta-
analysis, the cure rates for tigecycline were low for the
osteomyelitis substudy. Thirdly, tigecycline monotherapy could
not cover pseudomonas aeruginosa which is naturally resistant to
tigecycline.30–33 It is noted that there was an increase in incidence
of HAP caused by pseudomonas aeruginosa, from 9.6% in 1975 to
18.1% in 2003,34 which may be iatrogenic and associated with poor
outcome.35,36 This may explain the lower efﬁcacy in HAP. Fourthly,
as tigecycline has been used in clinic for about a decade,
tigecycline-resistant strains are emerging with reported isolates
of tigecycline-resistant klebsiella pneumonia,37,38 Escheichia coli38
and acinetobacter baumannii strain.39 Studies that veriﬁed higher
efﬁcacy of high-dose tigecycline for extremely resistant Gram-
negative pneumonia were identiﬁed.40 We also identiﬁed onestudy24 of two high-dosage tigecycline regimens for HAP with
numerically higher clinical response in the higher dosage. We
therefore recommend a high dose of tigecycline to be used in
failure cases with standard treatment. On the other hand, more
trials of efﬁcacy and safety of high-dosage tigecycline are
warranted. Also, we recommend tigecycline to be used in
conjunction with antibiotics to cover the wide range of bacteria
in polymicrobial infection. The microbiological treatment success
is lower in the tigecycline group than the control group but the
difference is not statistically signiﬁcant. Microbiological eradica-
tion rate is decreased in the subgroup of HAPs, cIAIs, cSSSIs, VRE
infections and MRSA infections in the tigecycline group with no
signiﬁcant difference. The eradication rates of speciﬁc microor-
ganism were diverse with no signiﬁcance difference for most of
them. There was, however, higher eradication rate of Streptococcus
spp. with signiﬁcant difference. This would provide support for
empirical use of tigecycline in severe CAP as the most prevalent
pathogen in CAP is Streptococcus spp.
In our meta-analysis, tigecycline had a signiﬁcantly increased
incidence of total AEs and SAEs, which is consistent with published
Table 2
Results of meta-analysis comparison of tigecycline and comparator drugs
Outcomes of interest Studies,no. Tigecycline
patients, no.
Comparator,
patients, no.
Odds ratio (95%CI) P value* Study heterogeneity
Chi2 df I2,% p value*
Primary outcomes
Cure rate of CE population 14 2833 2830 0.83[0.73, 0.96] 0.01 17.15 14 18 0.25
Cure rate of c-mITT population 10 2835 2782 0.81 [0.72, 0.92] 0.001 10.44 9 14 0.32
Cure rate of ME population 12 1483 1393 0.94 [0.77, 1.16] 0.56 10.71 11 0 0.47
Cure rate of m-mITT population 8 1394 1310 0.91 [0.74, 1.11] 0.35 5.42 7 0 0.61
Secondary outcomes
Any adverse events (AEs) 12 3193 3099 1.49 [1.23, 1.80] <0.0001 32.76 12 63 0.001
Serious adverse events 14 3374 3289 1.18 [1.03, 1.35] 0.02 9.40 13 0 0.74
AEs of digestive system 8 2032 1942 2.08 [1.53, 2.83] <0.00001 30.29 7 77 <0.0001
AEs of hemic and lymphatic system 6 1491 1487 1.24 [0.99, 1.55] 0.06 7.46 5 33 0.19
AEs of cardiovascular system 4 1178 1173 0.68 [0.52, 0.88] 0.004 2.25 3 0 0.52
AEs of metabolic and nutritional 6 1491 1487 0.96 [0.79, 1.16] 0.66 5.81 5 14 0.33
AEs of respiratory system 3 597 593 0.70 [0.43, 1.14] 0.15 0.28 2 0 0.87
All-cause mortality 14 3824 3680 1.33 [1.03, 1.72] 0.03 4.18 13 0 0.99
Eradication of Bacteroides fragilis 5 207 195 0.87 [0.56, 1.35] 0.54 1.43 4 0 0.84
Eradication of E. Coli 10 639 644 0.96 [0.72, 1.29] 0.81 4.93 9 0 0.84
Eradication of Klebsiella pneumonia 8 251 259 0.58 [0.32, 1.06] 0.08 3.44 6 0 0.75
Eradication of MRSA 8 149 193 0.70 [0.47, 1.06] 0.09 8.37 8 4 0.40
Eradication of MSSA 9 385 454 0.63 [0.44, 0.91] 0.01 4.59 9 0 0.87
Eradication of Enterococcus faecalis 7 174 237 1.14 [0.65, 2.02] 0.65 5.06 7 0 0.65
Eradication of Streptococcus spp. 11 382 365 1.54 [1.03, 2.30] 0.03 6.53 10 0 0.77
CI = conﬁdence interval, df = degree of freedom, *signiﬁcance set at P value < 0.05.
Figure 6. Forest plot and meta-analysis of any adverse events. M-H=Mantel-Haenszel method.
Figure 7. Forest plot and meta-analysis of serious adverse events. M-H=Mantel-Haenszel method.
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Figure 8. Forest plot and meta-analysis of all-cause mortality. M-H=Mantel-Haenszel method.
F. Shen et al. / International Journal of Infectious Diseases 39 (2015) 25–3332meta-analyses.6–8 Adverse events of digestive system are much
more frequent in the tigecycline regimen than in the comparator
regimens with nausea and vomiting as the most often reported
adverse reactions. Tigecycline is also associated with signiﬁcantly
higher frequency of adverse events in the body as a whole
including chills, fever, headache and pain. Adverse events of the
hemic and lymphatic system, metabolic and nutritional system
and respiratory system do not show signiﬁcant differences
between tigecycline and other antibiotics.
All-cause mortality rate was signiﬁcantly higher with tigecy-
cline versus comparators, which is consistent with FDA data and
the meta-analysis conducted by Yahav et al.8 We agree with Yahav
that the increased mortality is probably due to less clinical efﬁcacy,
which results in higher noncure rates and delayed clearance of
bacteremia, rather than fatal AEs.
Between-study heterogeneity was not signiﬁcant for all
primary outcomes and most of the secondary outcomes except
for any adverse events and adverse events of digestive system.
Meta–regression analysis revealed no signiﬁcant effect of year of
publication, study design, mITT population, types of infection,
comparator drugs, treatment duration and risk of bias.
The meta-analysis had some limitations that must not be
overlooked. Firstly, the meta-analysis did not include all eligibleFigure 9. Funnel plots illustrating meta-analysis of clinical cure rate of CE
population. SE = standard error; OR = odds ratio.data but only included ﬁfteen published RCTs. Three identiﬁed
studies searched by hand were not included in the meta-analysis
due to lack of approach to abstract and full-text. Unpublished data
and conference abstracts were not included. Secondly, lack of data
from some trials had led to fewer than the ﬁfteen originally
identiﬁed studies included in meta-analysis for most outcomes of
interest. We could have contacted researchers directly for missing
data, but failed to conduct the attempt because of time constraints.
Thirdly, inadequate random sequence generation and blinding and
non-available access to study protocol tended to increase the risk
of bias.
5. Conclusions
This meta-analysis indicates that tigecyline is not as effective as
standard antibiotic regimens for infectious diseases. Tigecycline is
associated with more frequency of adverse events and higher
mortality rate. We recommend tigecycline should be reserved as
the last option and closely monitored for adverse effects when
prescribed. Future large-volume, well-designed RCTs that focus on
efﬁcacy and safety of high-dosage of tigecycline are undoubtedly
desirable to conﬁrm the application of high-dosage of tigecycline.
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